8-K: BioAtla Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical Program Updates

BioAtla reported its Q4 and full year 2023 financial results, highlighting progress in its clinical programs and upcoming data readouts.

Summary

• BioAtla announced its financial results for the fourth quarter and full year ended December 31, 2023, along with updates on its clinical programs.
• The company's cash balance at the end of 2023 was $111.5 million, which is expected to fund operations into the second half of 2025.
• Research and development expenses for the quarter were $22.7 million, an increase of $0.8 million compared to the same quarter in 2022.
• General and administrative expenses for the quarter were $5.9 million, a decrease of $0.8 million compared to the same quarter in 2022.
• The net loss for the quarter was $26.9 million, compared to a net loss of $27.6 million for the same quarter in 2022.
• Net cash used in operating activities for the full year was $104.0 million, compared to $90.4 million in 2022.
• The company anticipates several key data readouts in the second quarter of 2024, including Phase 2 data for CAB-CTLA-4 (BA3071) and CAB-ROR2-ADC (BA3021).
• Enrollment for the CAB-AXL-ADC (BA3011) Phase 2 study in undifferentiated pleomorphic sarcoma is expected to complete in April, with an FDA meeting anticipated in the second half of 2024.
• The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is on track for a full data readout in the second half of 2024, with a potential Phase 2 study initiation in the same period.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and a clear path forward. The financial results are stable, and the company has sufficient cash to operate into 2025. However, the company is still in the clinical stage and faces inherent risks in drug development.

Positives

• The company has a strong cash position of $111.5 million, expected to fund operations into the second half of 2025.
• Multiple clinical programs are progressing with key data readouts anticipated in the near term.
• The CAB-CTLA-4 program has cleared a key safety hurdle, and is moving into Phase 2.
• The CAB-ROR2 program has completed enrollment in Phase 2 trials.
• The CAB-AXL program is on track to complete enrollment and engage with the FDA.
• The CAB-EpCAM x CAB-CD3 program is progressing through Phase 1 with a potential Phase 2 initiation in the second half of 2024.
• The novel anti-Nectin-4-ADC (BA3361) has shown promising preclinical results.
• The company is engaging with potential pharmaceutical partners to accelerate development and maximize the value of selected assets.

Negatives

• The company experienced a net loss of $26.9 million for the quarter ended December 31, 2023.
• Net cash used in operating activities for the full year was $104.0 million, an increase compared to $90.4 million in 2022.
• Cash and cash equivalents decreased from $215.5 million at the end of 2022 to $111.5 million at the end of 2023.

Risks

• The company's clinical trials may face potential delays.
• There are inherent uncertainties in research and development, including the ability to meet anticipated clinical endpoints.
• Regulatory authorities may not be satisfied with the design of and results from the clinical studies.
• The company is dependent on the success of its CAB technology platform.
• The company's ability to enroll patients in ongoing and future clinical trials is a risk.
• The company relies on third parties for the manufacture and supply of product candidates and to conduct clinical trials.
• The company may face potential adverse impacts due to any resurgence of COVID-19 and its variants.

Future Outlook

The company expects its current cash and cash equivalents to be sufficient to fund operations into the second half of 2025. They also anticipate several key data readouts and regulatory interactions in the coming quarters and are engaging with potential pharmaceutical partners to accelerate development.

Management Comments

• Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc., stated that BioAtla continued to make considerable progress in 2023 across both of our CAB-ADC clinical trials targeting multiple tumor types, as well as advancing our CAB-CTLA-4 clinical asset, BA3071.
• Management is excited to have several upcoming important milestones in the second quarter of this year including: initial data readouts from our Phase 2 BA3071 study; Phase 2 data for CAB-ROR2-ADC, BA3021, in both melanoma and head and neck cancer; and evaluation of clinical benefit in AXL-agnostic patients in our CAB-AXL-ADC, BA3011, Phase 2 NSCLC extension study.

Industry Context

BioAtla is operating in the competitive biotechnology sector, focusing on novel antibody therapeutics for solid tumors. The company's CAB technology aims to improve efficacy and reduce toxicity compared to traditional antibodies. The focus on multiple tumor types and combination therapies aligns with current trends in immuno-oncology.

Comparison to Industry Standards

• BioAtla's approach with Conditionally Active Biologics (CABs) is a differentiated strategy compared to traditional antibody development, aiming for improved tumor selectivity and reduced off-target effects.
• The company's focus on antibody-drug conjugates (ADCs) like BA3021 and BA3011 aligns with the industry trend of developing targeted therapies with enhanced efficacy.
• The development of a CAB-CTLA-4 antibody (BA3071) to potentially reduce systemic toxicity is a notable approach, as traditional CTLA-4 inhibitors are known for their side effects.
• The company's progress in bispecific T-cell engagers (BA3182) is also in line with the industry's interest in leveraging the immune system to fight cancer.
• Compared to companies like Seagen and ImmunoGen, which are leaders in the ADC space, BioAtla is still in the clinical stage, but its CAB technology offers a unique approach.
• Companies like Regeneron and Bristol Myers Squibb are also developing bispecific antibodies, and BioAtla's CAB-based approach could offer a competitive advantage.
• The company's cash runway into the second half of 2025 is a positive sign, but it will need to continue to raise capital to fund its ongoing clinical programs.

Stakeholder Impact

• Shareholders can expect updates on clinical trial progress and potential partnerships.
• Employees will continue to work on advancing the company's clinical programs.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors will continue to engage with the company as it progresses.

Next Steps

• The company will continue to enroll patients in its ongoing clinical trials.
• BioAtla will prepare for upcoming data readouts from its Phase 2 trials.
• The company will engage with the FDA regarding the CAB-AXL-ADC (BA3011) registration trial.
• BioAtla will continue to advance its Phase 1 study of CAB-EpCAM x CAB-CD3 (BA3182).
• The company will submit an IND for the anti-Nectin-4-ADC (BA3361).
• BioAtla will engage with potential pharmaceutical partners to accelerate development and maximize the value of selected assets.

Key Dates

Keywords

BioAtla, CAB, antibody therapeutics, clinical trials, oncology, cancer, BA3071, BA3021, BA3011, BA3182, BA3361, ADC, CTLA-4, ROR2, AXL, EpCAM, CD3, Nectin-4, biotechnology, pharmaceutical